Anti-ribosomal P protein antibody: an autoreactivity devoid of prognostic value in patients with autoimmune hepatitis

2014 ◽  
Vol 34 (9) ◽  
pp. 1446-1446 ◽  
Author(s):  
Luigi Muratori ◽  
Chiara Masi ◽  
Paolo Muratori
2014 ◽  
Vol 35 (2) ◽  
pp. 676-676 ◽  
Author(s):  
Ana L. Calich ◽  
Eloisa Bonfá

2013 ◽  
Vol 33 (6) ◽  
pp. 909-913 ◽  
Author(s):  
Ana L. Calich ◽  
Vilma S. T. Viana ◽  
Eduardo Cancado ◽  
Francisco Tustumi ◽  
Débora R. B. Terrabuio ◽  
...  

2020 ◽  
Vol 43 (2) ◽  
pp. 159
Author(s):  
Zikry Aulia Hidayat

Objective: Systemic lupus erythematosus (SLE) is a complex autoimmune disease involving many systems. Highest incidence and prevalence of SLE is found in Northern America 23.2/100,000 population/year and 241/100,000 population. According to sex differences, SLE is predominantly occurs in women than men with ratio 15:1 to 22:1. This discrepancy often causes delay in diagnosing SLE in male patients. Method: Case report. Result: We reported a male patient aged 21 years with pain of his joints, hyperpigmentation lesions on his face, alopesia, oral ulcers and decrease of body weight. Laboratory results showed increases in AST, ALT and D-Dimer, and from ANA Profile examination we got several positives results such as RNP/Sm (RNP/Sm) (++), Sm (Sm) (+), Ro-52 recombinant (52) (+), PCNA (PCNA) (+), DsDNA (DNA) (+), Nucleosome (NUC) (+), Histone (HI) (++), Ribosomal-P-protein (RIB) (+++) dan AMA-M2 (M2) (+). This patient met SLE criteria based on ACR 1997, SLICC 2012 and EULAR/ACR 2018. Patient was given oral methyl prednisolone 16-16-8 mg and VTE prophylaxis with subcutaneous heparin 2x5000 IU. Conclusion: SLE occurs rarely in male patients than female patients and has more diverse manifestations.


Toxins ◽  
2018 ◽  
Vol 10 (8) ◽  
pp. 335 ◽  
Author(s):  
Wei-Wei Shi ◽  
Kam-Bo Wong ◽  
Pang-Chui Shaw

Trichosanthin (TCS) is an RNA N-glycosidase that depurinates adenine-4324 in the conserved α-sarcin/ricin loop (α-SRL) of rat 28 S ribosomal RNA (rRNA). TCS has only one chain, and is classified as type 1 ribosome-inactivating protein (RIP). Our structural studies revealed that TCS consists of two domains, with five conserved catalytic residues Tyr70, Tyr111, Glu160, Arg163 and Phe192 at the active cleft formed between them. We also found that the structural requirements of TCS to interact with the ribosomal stalk protein P2 C-terminal tail. The structural analyses suggest TCS attacks ribosomes by first binding to the C-terminal domain of ribosomal P protein. TCS exhibits a broad spectrum of biological and pharmacological activities including anti-tumor, anti-virus, and immune regulatory activities. This review summarizes an updated knowledge in the structural and functional studies and the mechanism of its multiple pharmacological effects.


1996 ◽  
pp. 721-726 ◽  
Author(s):  
Eloisa Bonfa ◽  
Herbert Weissbach ◽  
Nathan Brot ◽  
Keith B. Elkon
Keyword(s):  

Medicine ◽  
2020 ◽  
Vol 99 (20) ◽  
pp. e20192
Author(s):  
Yanping Wang ◽  
Peng Luo ◽  
Ting Guo ◽  
Lin Zou ◽  
Jing Shi ◽  
...  

2014 ◽  
Vol 24 (6) ◽  
pp. 939-944 ◽  
Author(s):  
Shunsei Hirohata ◽  
Tsuyoshi Kasama ◽  
Yutaka Kawahito ◽  
Katsuhiko Takabayashi

Autoimmunity ◽  
2005 ◽  
Vol 38 (1) ◽  
pp. 85-92 ◽  
Author(s):  
Roberto Gerli ◽  
Laura Caponi
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document